Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib plus best supportive care versus placebo in chemotherapy-naive advanced non-small cell lung cancer with poor performance status
2004-004206-25Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Iressa + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Nov 2004; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-004206-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004206-25.